Yakira Capital Urges Atrium Therapeutics to Review Strategy and Spending
Yakira Capital urged Atrium Therapeutics’ board to explore strategic alternatives, curb cash spending and explain its $50 million financing. The firm cited a roughly 44% share-price decline and a valuation near half of net cash.
Story updates
12:12:02 PM UTC
SquawkNews
Yakira Capital Management, a shareholder of Atrium Therapeutics, publicly urged the Board to start a strategic review, cut spending, and explain its ~$50M private placement done at ~$7.93 per share after a ~44% stock drop.Material DetailsContext by AI AnalystThis is an activist push challenging cap…